Table 2: Characteristics of four patients with Bullous Pemphigoid induced by DPP4i.
Age (gender) |
Comorbillities |
Drug (Dose) |
Clinical Manifestation (Latency) |
Treatment (duration)/maintenance |
Response (time) |
Evolution (time) |
Number of prescription drugs |
81 (F) |
T2DM, CKD, SAH, HF, COPD, |
Linagliptin (5 mg) |
Non-bullous phase and bullous phase (4 months) |
Drug withdrawal, doxycycline (200 mg/d), prednisone 30 mg/day (1 year)/Azathioprine (50 mg/day) |
Partial (2 month) |
Chronic (2 years) |
6 |
83 (M) |
T2DM, SAH |
Linagliptin (5 mg) |
Non-bullous phase and bullous phase (1 year) |
Drug withdrawal, prednisone 20 mg/d (1 year) doxycycline (100 mg/day)/prednisone 10 mg |
Partial (3 month) |
Chronic (2 years) |
13 |
70 (F) |
HF, T2DM, HCV, Ampullary cancer |
Sitagliptin (100 mg) |
Non-bullous phase and bullous phase (1 week) |
Drug withdrawal, prednisone 15 mg/day (on track) |
Partial (1 week) |
Ontrack |
3 |
87 (M) |
T2DM, dyslipidemia, CKD, HF |
Linagliptin (5 mg)
|
Bullous phase (1 month) |
Drug withdrawal, prednisone 20 mg/day, topic clobetasol lymecycline 150 mg/day |
Complete (5 months) |
Chronic (5 months) |
10 |